Below are the NCI Cooperative Group active protocol list within the HCC Clinical Trials Network program. If you wish to access the cooperative group protocol documents and updates, please use the cooperative group links below. Protocol documents are available to cooperative group members who have an active username and password. If you are having difficulty accessing a protocol document, contact your research coordinator or the Network office.

last updated February 15, 2013

>

Disease Site	Coop Protocol Number	Protocol Title	CTN Member
Breast	NSABP B-39/ RTOG 0413	A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer	Georgetown Hospital System PI: Eric Aguero, MD
Breast	ACOSOG Z1031	A Randomized Phase III Trial Comparing 16 to 18 weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg) or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer	Hilton Head Regional Medical Center PI: Virginia Herrmann, MD(closed to accrual)
Thoracic	CALGB 30610/ RTOG 0538	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide	Georgetown Hospital System PI: Eric Aguero, MD Withdrawn
Breast	ACOSOG Z1071	A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis	Hilton Head Regional Medical Center PI: Virginia Herrmann, MD (closed to accrual)
Breast	SWOG 1007	A Phase III Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy /- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less	Self Regional Healthcare PI: Joanna Sadurski, MD
All Programs	SWOG 0702	A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment	Self Regional Healthcare PI: Joanna Sadurski, MD Georgetown Hospital System PI: David Lee Milling, MD (Pending)
Breast	NSABP B-47	A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Sic Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer	Self Regional Healthcare PI: Joanna Sadurski, MD Georgetown Hospital System PI: Darren Mullins, MD
Head and Neck	RTOG 1016	Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer	Self Regional Healthcare PI: Joanna Sadurski, MD (pending)
Thoracic	ECOG 1505	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Self Regional Healthcare PI: Joanna Sadurski, MD
Breast	CCCWF 97609	Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity	Self Regional Healthcare PI: Joanna Sadurski, MD
Breast	NSABP B-49	A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	Self Regional Healthcare PI: Joanna Sadurski, MD
Breast	ACOSOG 11102	Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)	Hilton Head Regional Medical Center PI: Virginia Herrmann, MD (pending)
Thoracic	ECOG 5508	Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC	Georgetown Hospital System PI: David Lee Milling, MD
GI	CALGB 80702	A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer	Georgetown Hospital System PI: David Lee Milling, MD